Skip to main content

Veterinary Pain Management Market worth $2.5 billion by 2027 – Exclusive Report by MarketsandMarkets™

Chicago, Oct. 14, 2022 (GLOBE NEWSWIRE) — Veterinary Pain Management Market is projected to grow from USD 1.8 billion in 2022 to USD 2.5 billion by 2027, at a CAGR of 6.7% from 2022 to 2027, according to a new report by MarketsandMarkets™. The Pain is the physiological term to describe the chemical processes that are at work in the body that receive a stimulus, modify it, and transfer it to the brain for interpretation and reaction. The stimulus can be physical, temperature, chemical, or inflammatory damage to tissues. In veterinary practices, pain management is achieved through analgesic drugs and devices.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=96167677

Browse in-depth TOC on “Veterinary Pain Management Market
299 – Tables
56 – Figures
298 – Pages

In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.

“NSAIDs is expected to witness the fastest growth market by drug type during the forecast period.”

The veterinary pain management market is segment into NSAIDs, opioids, local anesthetics, alpha-2 agonists, disease-modifying osteoarthritis drugs, and other drugs on the basis of drug type. In 2021, the NSAIDs segment accounted for largest share of the veterinary pain management drugs market. The large share of this segment can be attributed to the widespread adoption of NSAIDs in a wide range of applications due to the low cost of these drugs.

“Oral segment is expected to witness the fastest growth in the forecast period.”

The veterinary pain management drugs market is segment into oral, parenteral, and topical on the basis of route of administration. The oral segment accounted for the largest share of the veterinary pain management drugs market by route of administration in 2021. The oral administration segment held the largest share because orally administered drugs are convenient, easy to store, do not require special training, and are affordable.

“Joint pain accounted for the largest share of by veterinary pain management market by application in 2021”

Based on applications, the veterinary pain management market is segmented into joint pain, post-operative pain, cancer, and other applications. The joint pain segment accounted for the largest share of the market in 2021. The large share of this segment can be attributed to the growing geriatric pet population, the growing prevalence of osteoarthritis and musculoskeletal disorders, and the increasing population of obese and overweight pets.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=96167677

“Asia Pacific region is expected to witness the fastest growth during the forecast period”

On the basis of region, the veterinary pain management market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. The Asia Pacific market is estimated to grow at the highest CAGR during the forecast period and countries such as Japan, China, and India are expected to provide significant growth opportunities for market players. These countries have a large livestock population, as well as a growing trend of pet ownership.

Key Market Players:

The prominent players in the veterinary pain management market are Boehringer Ingelheim International GmbH (Germany), Zoetis Inc. (US), Elanco Animal Health Incorporated (US), Merck & Co., Inc. (US), Dechra Pharmaceuticals (UK), Vetoquinol (France), SeQuent Scientific Limited (India), Norbrook Laboratories Limited (Ireland), Ceva Santé Animale (France), Chanelle Pharma (Ireland), and K-Laser USA (US). New product launches and acquisitions were the major strategies adopted by these payers to maintain their positions in the market.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=96167677

Browse Adjacent Market: Medical Devices Market Research Reports & Consulting

Related Reports:

Veterinary Vaccines Market by Disease (Swine Pneumonia, Avian Influenza, Rabies, Coccidiosis, Brucellosis, Canine Distemper), Type (Poultry, Livestock, Aquaculture, Porcine, Canine), Technology (Inactivated, Toxoid, Recombinant) – Global Forecast to 2025

CONTACT: About MarketsandMarkets™ 

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.